New approaches to the treatment of acute respiratory viral infections and the prevention of bacterial complications: A review

Cover Page

Cite item

Full Text

Abstract

The article discusses the current problems of the treatment of acute respiratory infections, excessive use of antibiotics and the growth of resistance to them, which is ahead of the development of effective antimicrobial drugs. The results of the research of a new drug (Rafamin) are presented. Rafamin is combining antiviral and antibacterial effects, and may be in demand both for the treatment of acute respiratory viral infections and for the prevention of bacterial complications. The mechanism of action of the drug is associated with the activation of immune mechanisms involved in the recognition of pathogens of both viral and bacterial nature and the launch of a subsequent humoral and cellular response that ensures the elimination of the pathogen. The effects of Rafamin are realized due to targeted effects on the system of the major histocompatibility complex, interferon gamma and CD4-receptor of T-lymphocytes.

About the authors

Nina A. Miroshnichenko

Yevdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: mirnino@yandex.ru
ORCID iD: 0000-0003-4213-6435

D. Sci. (Med.)

Russian Federation, Moscow

Nikolai I. Lvov

Kirov Military Medical Academy

Email: 05011912@mail.ru
ORCID iD: 0000-0003-4254-229X

D. Sci. (Med.)

Russian Federation, Saint Petersburg

References

  1. Jamison DT, Breman JG, Measham AR, et al., ed. Disease Control Priorities in Developing Countries. 2nd ed. Washington (DC): The International Bank for Reconstruction and Development. The World Bank, 2006. Available at: https://www.ncbi.nlm.nih.gov/books/NBK11728/ Accessed: 10.03.2022.
  2. Острый синусит. Клинические рекомендации. Режим доступа: http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv1.pdf. Ссылка активна на 10.02.2022 [Ostryi sinusit. Klinicheskie rekomendatsii. Available at: http://www.fesmu.ru/SITE/files/editor/file/fpk_pps/rv1.pdf. Accessed: 10.02.2022 (in Russian)].
  3. Фазылов В.Х., Ситников И.Г., Малышев Н.А., и др. Влияние противовирусной терапии на частоту развития бактериальных осложнений и назначения антибактериальных препаратов для системного использования у пациентов с ОРВИ и гриппом (результаты международного когортного наблюдательного исследования FLU-EE). Антибиотики и химиотерапия. 2016;61(11-12):39-47 [Fazylov VC, Sitnikov IG, Malyshev NA, et al. The Effect of Antiviral Therapy on the Incidence of Bacterial Aggravations and Administration of Systemic Antibiotics in Patients with Acute Respiratory Viral Infections and Influenza (Results of International Cohort Observational Study). Antibiotics and Chemotherapy. 2016;61(11-12):39-47 (in Russian)].
  4. Дифференциальная диагностика и лечение острого тонзиллфарингита. Клинические рекомендации. Режим доступа: https://lornii.ru/upload/iblock/464/%D0%9E%D1%81%D1%82%D1%80%D1%8B%D0%B9%20%D1%82%D0%BE%D0%BD%D0%B7%D0%B8%D0%BB%D0%BB%D0%BE%D1%84%D0%B0%D1%80%D0%B8%D0%BD%D0%B3%D0%B8%D1%82.pdf. Ссылка активна на 10.03.2022 [Differentsial'naia diagnostika i lechenie ostrogo tonzillfaringita. Klinicheskie rekomendatsii. Available at:10.02.2022 https://lornii.ru/upload/iblock/464/%D0%9E%D1%81%D1%82%D1%80%D1%8B%D0%B9%20%D1%82%D0%BE%D0%BD%D0%B7%D0%B8%D0%BB%D0%BB%D0%BE%D1%84%D0%B0%D1%80%D0%B8%D0%BD%D0%B3%D0%B8%D1%82.pdf. Accessed: 10.03.2022 (in Russian)].
  5. Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645-58. doi: 10.2147/IDR.S173867
  6. Геппе Н.А., Валиева С.Т., Фараджева Н.А., и др. Лечение ОРВИ и гриппа в амбулаторно- поликлинической практике: результаты международной наблюдательной неинтервенционной программы «Эрмитаж». Терапия. 2017;8(18):63-78 [Geppe NA, Vаliyeva ST, Farajova NA, et al. Treatment of ARVI and grippe in ambulatory-polyclinical practice: results of international observing non-interventional programme "Ermitage". Therapy. 2017;8(18):63-78 (in Russian)].
  7. Read AF, Woods RJ. Antibiotic resistance management. Evol Med Public Health. 2014;2014(1):147. doi: 10.1093/emph/eou024
  8. Martinez JL. The role of natural environments in the evolution of resistance traits in pathogenic bacteria. Proc Biol Sci. 2009;276(1667):2521-30.
  9. Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016;4(2):10.1128/microbiolspec.VMBF-0016-2015. doi: 10.1128/microbiolspec.VMBF-0016-2015
  10. Wellington EM, Boxall AB, Cross P, et al. The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect Dis. 2013;13(2):155-65. doi: 10.1016/S1473-3099(12)70317-1
  11. Kristiansson E, Fick J, Janzon A, et al. Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and gene transfer elements. PLoS One. 2011;6(2):e17038.
  12. Lye DC, Earnest A, Ling ML, et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect. 2012;18(5):502-8.
  13. Weber T. In silico tools for the analysis of antibiotic biosynthetic pathways. Int J Med Microbiol. 2014;304(3-4):230-5.
  14. Теймуразов М.Г., Петрова Н.В., Карелина Е.А., и др. Доклиническое изучение эффективности нового иммунотропного препарата при лечении сальмонеллезной инфекции. Бюллетень сибирской медицины. 2021;20(2):95-101 [Teymurazov MG, Petrova NV, Karelina EA, et al. Nonclinical study of the new immunotropic drug effectiveness in salmonella infection treatment. Bulletin of Siberian Medicine. 2021;20(2):95-101 (in Russian)]. doi: 10.20538/1682-0363-2021-2-95-101
  15. Петрова Н.В., Емельянова А.Г., Тарасов С.А., и др. Результаты доклинического исследования эффективности экспериментального препарата на основе технологически обработанных антител на моделях гриппа и смешанной вирусно-бактериальной инфекции. Патогенез. 2020;18(4):55-63 [Petrova NV, Emelianova AG, Tarasov SA, et al. Efficacy of an experimental drug based on technologically processed antibodies in models of influenza infection and secondary bacterial pneumonia: Results of a preclinical study. Patogenez. 2020;18(4):55-63 (in Russian)]. doi: 10.25557/2310-0435.2020.04.55-63
  16. Iannello A, Debbeche O, Martin E, et al. Viral strategies for evading antiviral cellular immune responses of the host. J Leukoc Biol. 2006;79(1):16-35. DOI:0.1189/jlb.0705397
  17. Emelianova AG, Petrova NV, Fremez C, et al. Therapeutic potential of highly diluted antibodies in antibiotic-resistant infection. European Journal of Pharmaceutical Sciences. 2022;173:106161. doi: 10.1016/j.ejps.2022.106161
  18. Petrova N, Don E, Emelyanova A, et al. Screening research of antibacterial potential of selected released-active forms of antibodies. 30th European Congress of Clinical Microbiology and Infectious Diseases. Paris, France. April 18–21, 2020:2966.
  19. Хамитов Р.Ф., Никифоров В.В., Зайцев А.А., Трагира И.Н. Оценка эффективности и безопасности комплексного противовирусного препарата на основе антител в терапии взрослых больных острой респираторной вирусной инфекцией. Терапевтический архив. 2022;94(1):83-93 [Khamitov RF, Nikiforov VV, Zaytsev AA, Tragira IN. Evaluation of the efficacy and safety of a complex antiviral drug based on antibodies in the treatment of adult patients with acute respiratory viral infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(1):83-93 (in Russian)]. doi: 10.26442/00403660.2022.01.201345
  20. Клинические исследования по препарату Рафамин. Режим доступа: https://clinicaltrials.gov/ct2/results?cond=&term=MMH-407&cntry=&state=&city=&dist= Ссылка активна на 10.02.2022 [Klinicheskie issledovaniia po preparatu Rafamin. Available at: https://clinicaltrials.gov/ct2/results?cond=&term=MMH-407&cntry=&state=&city=&dist= Accessed: 10.02.2022 (in Russian)].

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies